Cohen Yuval's Form 4 filing
Corbus Pharmaceuticals Holdings, Inc. (CRBP) · filed Jun 18, 2024
- Accession no.
- 0000950170-24-075071
- Filed
- Jun 18, 2024
- Trade date
- Jun 14-18, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 15 non-derivative transactions and 7 derivative transactions. Open-market sales total $2.95M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cohen YuvalCIK 0001626003 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 14, 2024 | Common Stock, par value $0.0001 per share | MOption exerciseAcquired | +16,830 | $14.10 | +$237,303 | 101,230 | Direct | |
| Jun 14, 2024 | Common Stock, par value $0.0001 per share | SSaleDisposed | −16,830 | $50.17F3 | −$844,361.1 | 84,400 | Direct | |
| Jun 14, 2024 | Common Stock, par value $0.0001 per share | MOption exerciseAcquired | +12,487 | $4.26 | +$53,194.62 | 96,887 | Direct | |
| Jun 14, 2024 | Common Stock, par value $0.0001 per share | SSaleDisposed | −12,487 | $50.17F3 | −$626,472.79 | 84,400 | Direct | |
| Jun 17, 2024 | Common Stock, par value $0.0001 per share | MOption exerciseAcquired | +9,333 | $30.00 | +$279,990 | 93,733 | Direct | |
| Jun 17, 2024 | Common Stock, par value $0.0001 per share | SSaleDisposed | −9,333 | $46.02F4 | −$429,504.66 | 84,400 | Direct | |
| Jun 17, 2024 | Common Stock, par value $0.0001 per share | MOption exerciseAcquired | +1,770 | $4.26 | +$7,540.2 | 86,170 | Direct | |
| Jun 17, 2024 | Common Stock, par value $0.0001 per share | SSaleDisposed | −1,770 | $46.02F4 | −$81,455.4 | 84,400 | Direct | |
| Jun 18, 2024 | Common Stock, par value $0.0001 per share | MOption exerciseAcquired | +11,667 | $30.00 | +$350,010 | 96,067 | Direct | |
| Jun 18, 2024 | Common Stock, par value $0.0001 per share | SSaleDisposed | −11,667 | $42.24F5 | −$492,814.08 | 84,400 | Direct | |
| Jun 18, 2024 | Common Stock, par value $0.0001 per share | MOption exerciseAcquired | +1,770 | $14.10 | +$24,957 | 86,170 | Direct | |
| Jun 18, 2024 | Common Stock, par value $0.0001 per share | SSaleDisposed | −1,770 | $42.24F5 | −$74,764.8 | 84,400 | Direct | |
| Jun 18, 2024 | Common Stock, par value $0.0001 per share | MOption exerciseAcquired | +2,322 | $4.26 | +$9,891.72 | 86,722 | Direct | |
| Jun 18, 2024 | Common Stock, par value $0.0001 per share | SSaleDisposed | −2,322 | $42.24F5 | −$98,081.28 | 84,400 | Direct | |
| Jun 18, 2024 | Common Stock, par value $0.0001 per share | SSaleDisposed | −7,179 | $42.24F5 | −$303,240.96 | 77,221 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 14, 2024 | Common Stock | MOption exerciseDisposed | −16,830 | $0.00 | $0 | 32,827 | Direct | |
| Jun 14, 2024 | Common Stock | MOption exerciseDisposed | −12,487 | $0.00 | $0 | 53,831 | Direct | |
| Jun 17, 2024 | Common Stock | MOption exerciseDisposed | −9,333 | $0.00 | $0 | 11,667 | Direct | |
| Jun 17, 2024 | Common Stock | MOption exerciseDisposed | −1,770 | $0.00 | $0 | 52,061 | Direct | |
| Jun 18, 2024 | Common Stock | MOption exerciseDisposed | −11,667 | $0.00 | $0 | 0 | Direct | |
| Jun 18, 2024 | Common Stock | MOption exerciseDisposed | −1,770 | $0.00 | $0 | 31,057 | Direct | |
| Jun 18, 2024 | Common Stock | MOption exerciseDisposed | −2,322 | $0.00 | $0 | 49,739 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.27 to $52.23 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.0 to $49.38 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Referenced by the price of 2 transactions in Table I.
- F5
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.75 to $43.69 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Referenced by the price of 4 transactions in Table I.